BioStock: SynAct Pharma advances trial with boosted funding

In the fourth quarter, SynAct Pharma focused on progressing its Phase IIb study, ADVANCE, evaluating resomelagon in newly diagnosed severe rheumatoid arthritis patients. The company has also secured crucial funding to maintain its momentum. CEO Jeppe Øvlesen discusses the progress in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/02/synact-pharma-advances-trial-with-boosted-funding/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se